Universo Viviente
Related Articles
BOSTON, August 24, 2021 / PRNewswire / – MicroQuin Ltd, a preclinical biotechnology company that develops targeted therapies to treat diseases with critical needs, today announced that it has signed a Non-Clinical Assessment Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) to assess the potential of MicroQuin (MQP) therapies and direct them to clinical trials as treatments for a range of viruses including influenza, SARS-CoV-2, respiratory syncytial virus (RSV) and adenovirus. The company’s viral infection program has shown positive results in vitro with viral inhibition ranging from 75 to 99.5% depending on the virus.
MicroQuin Ltd will use NIAID’s suite of preclinical services to further screen for the efficacy of MQPs on a wide range of viruses and to assess their efficacy in relevant preclinical models.
“We are pleased to announce this agreement with NIAID to provide further evaluation of our MQPs, which have shown broad antiviral activity and significant viral inhibition in vitro. The NIAID Preclinical Services Program will further assess promising MQPs in models suitable for progression to the clinic, “said Dr. Robinson, Scientific Director of MicroQuin.” MicroQuin’s collaborative approach with various partners, such as the Center for the Advancement of Science in Space (CASIS) / NASA, has been the key to the success of our therapeutic development and our scientific validation “, he added.
MicroQuin hopes to accelerate its antiviral program to meet the world’s urgent need for effective treatment of a range of viral infections. For example, the four antivirals approved by the U.S. Food and Drug Administration to treat seasonal flu have shown limited effectiveness, working only to reduce symptoms and shorten the duration of illness by 1 to 2 days. The results of the company’s viral infection program have surpassed the effectiveness of the current influenza vaccine with viral inhibition of up to 99.5% in vitro.
About MicroQuin
MicroQuin Ltd is an IND stage preclinical biotechnology company focused on the research and development of breakthrough therapies against new, intact targets for the treatment of the world’s largest diseases. MicroQuin specializes in 3 key programs in oncology, antiviral and neurodegenerative. MicroQuin’s work on the International Space Station has revolutionized the way therapies are developed through the structural elucidation of intact targets that are integral to many diseases. To date, the company has discovered more than 75 therapeutics on 4 key targets that dramatically alter disease progression, offering hope to millions of patients.
For more information about the company, please visit www.microquin.com.
Contacts: [email protected]
Show original content:https://www.prnewswire.com/news-releases/microquin-enters-agreement-with-niaid-to-evaluate-microquin-therapeutics-for-the-treatment-of-viral-infections-301360623.html
SOURCE MicroQuin
